Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]RCCB6
- Development stage
- Phase 2
- Lead developer
- Renji Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[18F]RCCB6 is a radiolabeled single-domain antibody (sdAb) immunoPET imaging agent targeting CD70, a biomarker highly expressed in clear cell renal cell carcinoma (ccRCC). The tracer is developed by labeling the RCCB6 sdAb with fluorine-18 using the aluminium fluoride restrained complexing agent (AlF-RESCA) method. [18F]RCCB6 binds specifically to human CD70 and enables high-contrast PET/CT imaging of ccRCC tumors and metastases. Preclinical studies demonstrated its superior tumor-to-background ratio compared to other tracers, and early clinical trials have shown improved diagnostic accuracy over standard 18F-FDG PET/CT for detecting ccRCC lesions. Its primary use is for non-invasive detection, surveillance, and assessment of recurrence or metastasis in patients with clear cell renal cell carcinoma[1][3][4][5].
- Other names
- RESCA-RCCB6RESCA-RCCB-6RESCA-RCCB 6[18F]F-RESCA-RCCB6
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on [18F]RCCB6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]RCCB6.